Clinuvel Pharmaceuticals Limited (CLVLY)

USD 7.55

(0.0%)

Market Cap (In USD)

377.95 Million

Revenue (In USD)

88.17 Million

Net Income (In USD)

35.63 Million

Avg. Volume

1419.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
7.83-11.43
PE
-
EPS
-
Beta Value
0.853
ISIN
US1887691038
CUSIP
188769103
CIK
1290877
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Philippe Jacques Wolgen M.B.A., M.D.
Employee Count
-
Website
https://www.clinuvel.com
Ipo Date
2008-01-30
Details
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.